

Application No.: 10/081,555  
Filing Date: February 20, 2002  
Amendment in Response to Office Action (mailed 5/3/05) faxed 6/3/05  
Page 2 of 10

Attorney Docket No.: SALK2270-5  
(088802-5212)

**Amendments to the Claims/Listing of Claims**

Please amend claims 32 and 35-37, and add claims 38-40 as follows. This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Cancelled)
2. (Withdrawn) The method according to claim 4, wherein said SXR polypeptide is a member of the steroid/thyroid hormone superfamily and forms a heterodimer with retinoid X receptor, wherein said heterodimer binds to a direct or inverted repeat response element comprising at least two half sites RGBNNM separated by a spacer of 0 up to 15 nucleotides, wherein:  
R is selected from A or G;  
B is selected from G, C, or T;  
each N is independently selected from A, T, C, or G; and  
M is selected from A or C;  
with the proviso that at least 4 nucleotides of said RGBNNM sequence are identical with the nucleotides at corresponding positions of the sequence AGTTCA; and  
wherein said SXR polypeptide activates transcription of gene(s) under the control of cytochrome P450 response element in response to a wide variety of natural and synthetic steroid hormones, compounds that induce catabolic enzymes, steroid receptor agonists and antagonists, and bioactive dietary compounds.
3. (Withdrawn) A method for screening a collection of compounds to determine those compounds which bind to a SXR polypeptide, or functional fragments thereof, said method comprising employing an SXR polypeptide in a binding assay.
4. (Original) A method of testing a compound for its ability to regulate transcription-activating effects of a SXR polypeptide, said method comprising assaying for the

Application No.: 10/081,555  
Filing Date: February 20, 2002

Attorney Docket No.: SALK2270-5  
(088802-5212)

Amendment in Response to Office Action (mailed 5/3/05) faxed 6/3/05  
Page 3 of 10

presence or absence of reporter protein upon contacting a host cell containing said SXR polypeptide and a reporter vector with said compound, wherein said reporter vector comprises:

- (a) a promoter that is operable in said host cell,
- (b) a response element, and
- (c) DNA encoding a reporter protein,

wherein said DNA is operatively linked to said promoter for transcription of said DNA, and,

wherein said promoter is operatively linked to said SXR response element for activation thereof.

5. (Withdrawn) A method of identifying compounds which activate SXR polypeptide, but do not activate other members of the steroid/thyroid hormone superfamily, said method comprising:

(i) detecting in a first assay system the presence or absence of a first reporter protein upon contacting a first host cell with test compound(s), wherein said first host cell contains said SXR polypeptide and a first reporter vector, wherein said first reporter vector comprises:

- (a) a first promoter that is operable in said first host cell,
- (b) a SXR response element, and
- (c) a first DNA encoding a first reporter protein,

wherein said first DNA is operatively linked to said first promoter for transcription of said first DNA, and,

wherein said first promoter is operatively linked to said SXR response element for activation thereof;

(ii) detecting in a second assay system the presence or absence of a second reporter protein upon contacting a second host cell with test compound(s), wherein said second host cell contains a member of the steroid/thyroid hormone superfamily other than SXR and a second reporter vector, wherein said second reporter vector comprises:

- (a) a second promoter that is operable in said second host cell,

Application No.: 10/081,555  
Filing Date: February 20, 2002  
Amendment in Response to Office Action (mailed 5/3/05) faxed 6/3/05  
Page 4 of 10

Attorney Docket No.: SALK2270-5  
(088802-5212)

(b) a response element for said member of the steroid/thyroid hormone superfamily other than SXR, and  
(c) a second DNA encoding a second reporter protein,  
wherein said second DNA is operatively linked to said second promoter for transcription of said second DNA, and

wherein said second promoter is operatively linked to said response element for said member of the steroid/thyroid hormone superfamily other than SXR for activation thereof; and

(iii) identifying those compounds which induce production of a reporter protein in said first assay, but not in said second assay, as compounds which activate SXR polypeptide, but do not activate other members of the steroid/thyroid hormone superfamily.

6-26. (Cancelled)

27. (Withdrawn) The method of claim 4 wherein said host cells comprise cells transfected with an isolated or recombinant polynucleotide, wherein said polynucleotide encodes a SXR polypeptide, or functional fragments thereof,

wherein said SXR polypeptide is a member of the steroid/thyroid hormone superfamily and forms a heterodimer with retinoid X receptor,

wherein said heterodimer binds to a direct or inverted repeat response element comprising at least two half sites RGBNNM separated by a spacer of 0 up to 15 nucleotides,

wherein:

R is selected from A or G;

B is selected from G, C, or T;

each N is independently selected from A, T, C, or G; and

M is selected from A or C;

with the proviso that at least 4 nucleotides of said RGBNNM sequence are identical with the nucleotides at corresponding positions of the sequence AGTTCA; and

wherein said SXR polypeptide activates transcription of gene(s) under the control of cytochrome P450 response element in response to a wide variety of natural and synthetic steroid

Application No.: 10/081,555  
Filing Date: February 20, 2002  
Amendment in Response to Office Action (mailed 5/3/05) faxed 6/3/05  
Page 5 of 10

Attorney Docket No.: SALK2270-5  
(088802-5212)

hormones, compounds that induce catabolic enzymes, steroid receptor agonists and antagonists, and bioactive dietary compounds.

28. (Withdrawn) The method of claim 27 wherein said functional fragments of said SXR polypeptide comprise a ligand binding domain, a DNA binding domain or both.

29. (Withdrawn) The method of claim 27 wherein said host cells are further transfected with a vector which comprises:

- (a) a promoter that is operable in said cells;
- (b) a response element, and
- (c) DNA encoding a reporter protein,

wherein said DNA is operatively linked to said promoter for transcription of said DNA, and

wherein said promoter is operatively linked to said response element for activation thereof.

30-31. (Cancelled)

32. (Currently amended) The method of claim 4 wherein said promoter is selected from the group consisting of an albumin promoter/enhancer, a CYP3A cellular promoter, a CYP3A23 cellular promoter, a CYP3A2 promoter, a CYP3A3 promoter, a CYP3A4 cellular promoter, and a 3A6 promoter.

33. (Previously presented) The method of claim 4 wherein said response element is a direct or inverted repeat response element comprising at least two half sites RGBNNM separated by a spacer of 0 up to 15 nucleotides,

wherein:

R is selected from A or G;

B is selected from G, C, or T;

Application No.: 10/081,555  
Filing Date: February 20, 2002  
Amendment in Response to Office Action (mailed 5/3/05) faxed 6/3/05  
Page 6 of 10

Attorney Docket No.: SALK2270-5  
(088802-5212)

each N is independently selected from A, T, C, or G; and  
M is selected from A or C;  
with the proviso that at least 4 nucleotides of said RGBNNM sequence are identical with the  
nucleotides at corresponding positions of the sequence AGTTCA.

34. (Previously presented) The method of claim 33 wherein said response element is selected from the group consisting of an inverted repeat separated by a 6 nucleotide spacer (IR-6), a direct repeat separated by a 3 nucleotide spacer (DR-3), a direct repeat separated by a 4 nucleotide spacer (DR-4), and a direct repeat separated by a 5 nucleotide spacer (DR-5).

35. (Withdrawn-currently amended) The method of claim 34 wherein said response element is selected from the group consisting of:

AGGTCAN<sub>n</sub>AGGTCA,

wherein n is 3, 4, or 5 (SEQ ID NOS: 15, 16 and 17 NO:44);

AGTTCAN<sub>n</sub>TGAACt,

wherein n is 3, 4 or 5 (SEQ ID NO: 22); and

TGAACtN<sub>n</sub>AGGTCA), wherein n is 6 (SEQ ID NO:23).

36. (Currently amended) The method of claim [[35]] 34 wherein said response element is selected from the group consisting of:

tagac AGTTCA tga AGTTCA tctac (SEQ ID NO:3),  
~~taage AGTTCA taa AGTTCA tetac (SEQ ID NO:4),~~  
~~aetgt AGTTCA taa AGTTCA eatgg (SEQ ID NO:5),~~  
~~caata AGTTCA aacg GGTCA eeaat (SEQ ID NO:6),~~  
~~eae AGGTGA getg AGGCCA geage AGCTCG aea (SEQ ID NO:7),~~  
~~gtgea GGTCA aetgg AGGTCA aeatg (SEQ ID NO:8),~~  
~~gtget CCTTCA aetgg AGGTCA gtatg (SEQ ID NO:9),~~  
~~agtet AGTTCA gtggg CGTTCA gtatt (SEQ ID NO:10), and~~  
~~gagat GGTCA aggaa CGGTCA tttae (SEQ ID NO:11).~~

Application No.: 10/081,555 Attorney Docket No.: SALK2270-5  
Filing Date: February 20, 2002 (088802-5212)  
Amendment in Response to Office Action (mailed 5/3/05) faxed 6/3/05  
Page 7 of 10

37. (Currently amended) The method of claim 4 wherein said reporter protein is luciferase or  $\beta$ -galactosidase.

38. (New-Withdrawn) The method of claim 4 wherein said promoter is selected from the group consisting of an albumin promoter/enhancer, a CYP3A23 cellular promoter, a CYP3A2 promoter, a CYP3A3 promoter, a CYP3A4 cellular promoter, and a 3A6 promoter.

39. (New-Withdrawn) The method of claim 34 wherein said response element is selected from the group consisting of :

taagc AGTTCA taa AGTTCA tctac (SEQ ID NO:4),  
actgt AGTTCA taa AGTTCA catgg (SEQ ID NO:5),  
caatc AGTTCA acag GGTTCA ccaat (SEQ ID NO:6),  
cac AGGTGA gctg AGGCCA gcagc AGGTCG aaa (SEQ ID NO:7),  
gtgca GGTTCA actgg AGGTCA acatg (SEQ ID NO:8),  
gtgct GGTTCA actgg AGGTCA gtatg (SEQ ID NO:9),  
agtct AGTTCA gtggg GGTTCA gtctt (SEQ ID NO:10), and  
gagat GGTTCA aggaa GGGTCA ttaac (SEQ ID NO:11).

40. (New-Withdrawn) The method of claim 4 wherein said reporter protein is  $\beta$ -galactosidase.